Global Study Seeks to Unravel Secrets of 'Super Survivors' in Cancer Treatment
Doctors have launched the first global study aimed at understanding why certain cancer patients, dubbed 'super survivors', manage to excel in their recovery despite severe diagnoses. Named the Rosalind study, this initiative will compile data from large groups of these extraordinary patients.
Led by Dr. Thankamma Ajithkumar at Cambridge University Hospitals NHS Trust, the study seeks to examine patients with aggressive cancer types, including extensive-stage small cell lung cancer, glioblastoma, and metastatic pancreatic ductal adenocarcinoma, where only 3% to 5% of patients survive beyond five years following diagnosis.
Historically, survival disparities were often attributed to luck or chance, but Dr. Ajithkumar emphasizes the importance of scientific investigation to uncover reliable predictors of longevity. "We will have a much larger database to say more confidently that this is what is making you live longer," he stated.
Among those participating in the study is Katherine Webster, a stage four glioblastoma survivor who defied her prognosis after surgery and intensive treatment. "I never believed I was going to die," she reflected, highlighting the significance of a positive mindset throughout her battle.
The research will involve examination of biological data from more than 1,000 patients across over 40 countries, including contributions from eight UK cancer centers. Researchers aim not only to satisfy curiosity about survival mechanisms but also to potentially identify new drug targets for cancer treatment.
Co-founder of Cure51, the biotech startup overseeing the project, Nicolas Wolikow, expressed an ambitious goal: to "kill cancer" within 20 years by replicating the biological mechanisms seen in super survivors for broader patient populations.
Weekly Newsletter
News summary by melangenews